Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: An open-label extension study

Clinical Therapeutics

Volumn 24, Issue 9, 2002, Pages 1401-1413

  Garber, Alan J ^a   Bruce, Simon ^b   Fiedorek, Fred T ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Diabetes; Fasting plasma glucose.; Glyburide; Metformin

Indexed keywords

GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TABLET; TREATMENT OUTCOME; TREMOR; VERTIGO; VOMITING;

EID: 0036751099     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80044-3     Document Type: Article

References (14)

1. Siebert C, Lipsett LF, Greenblatt J, Silverman RE. Survey of physician practice behaviors related to diabetes mellitus in the U.S.I. Design and methods. Diabetes Care. 1993;16:759-764.
2. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. Atlanta, Ga: Centers for Disease Control and Prevention; 1998:1-8.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352: 854-865.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352: 837-853.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321: 405-412.
6. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
7. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21-B29.
8. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2001;24(Suppl):S33-S43.
9. Harris MI. Racial and ethnic differences in health insurance coverage for adults with diabetes. Diabetes Care. 1999;22:1679-1682.
10. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4:201-208.
11. Marathe PH, Arnold ME, Meeker J, et al. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol. 2000;40:1494-1502.
12. Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab. 1994;20:394-400.
13. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care. 1999;22:33-37.
14. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:136-145.